Beijing Weixiao Biotechnology Development

Beijing Weixiao Biotechnology Development is a Chinese biotechnology company and a subsidiary of Immunotech Biopharm (HKEX: 6978). The company specializes in the development of innovative cellular immunotherapies, with a primary focus on gynecological cancers. Its lead candidate, 6B11-OCIK Injection, is an autologous cytotoxic T lymphocyte therapy induced by the 6B11 humanized anti-idiotypic antibody, which mimics the ovarian cancer-related antigen OC166-9. Beijing Weixiao works in collaboration with institutions like Peking University People's Hospital to advance its pipeline of cell-based treatments for unmet medical needs in oncology. The company operates as a key research and development arm within the broader Immunotech Biopharm group, leveraging proprietary technology to create targeted cancer therapies.